Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet
Endocrine-Related Cancer · 06.07.2023 · 30 (9)
DOI: 10.1530/erc-23-0102 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, erschienen am 06.07.2023. Verfasst von Erin Gibbons und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Graphical abstract Abstract Lymphangioleiomyomatosis (LAM) is a cystic lung disease found almost exclusively in genetic females and caused by small clusters of smooth muscle cell tumors containing mutations in one of the two tuberous sclerosis genes ( TSC1 or TSC2 ). Significant advances over the past 2–3 decades have allowed researchers and clinicians to more clearly understand the pathophysiology of LAM, and therefore better diagnose and treat patients with this disease. Despite substantial progress, only one proven treatment for LAM is used in practice: mechanistic target of rapamycin complex 1 (mTORC1) inhibition with medications such as sirolimus. While mTORC1 inhibition effectively slows LAM progression in many patients, it is not curative, is not effective in all patients, and can be associated with significant side effects. Furthermore, the presence of established and accurate biomarkers to follow LAM progression is limited. That said, discovering additional diagnostic and treatment options for LAM is paramount. This review will describe recent advances in LAM research, centering on the origin and nature of the LAM cell, the role of estrogen in LAM progression, the significance of melanocytic marker expression in LAM cells, and the potential roles of the microenvironment in promoting LAM tumor growth. By appreciating these processes in more detail, researchers and caregivers may be afforded novel approaches to aid in the treatment of patients with LAM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
ORCID-Profile: Stephen R Hammes
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Gibbons, E., Minor, B. M. N., & Hammes, S. R. (2023). Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet. Endocrine-Related Cancer, 30(9). https://doi.org/10.1530/erc-23-0102
Vancouver
Gibbons E, Minor BMN, Hammes SR. Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet. Endocrine-Related Cancer. 2023;30(9). doi:10.1530/erc-23-0102
BibTeX
@article{Gibbons2023,
author = {Gibbons, Erin and Minor, Briaunna M N and Hammes, Stephen R},
title = {Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet},
journal = {Endocrine-Related Cancer},
year = {2023},
volume = {30},
number = {9},
doi = {10.1530/erc-23-0102}
}
EUVIMED